Karnataka: Shilpa Medicare has recently announced that the Company’s finished dosage form manufacturing facility, Unit IV, situated at
Pharma SEZ, Jadcherla, Telangana, has received Health Canada GMP approval.
The inspection was conducted
from September 12, 2022, to September 16, 2022.
The facility is involved in the manufacturing, packaging, labelling, and testing of finished dosage forms (sterile
injections and oral solids) for the treatment of cancer and adjuvant therapy.
This GMP approval will allow
the company for the commercial distribution of products in Canada and enable new application
submissions to Health Canada.
“This approval reaffirms the company’s focused efforts to maintain the GMP status up to the standards of
global regulatory authorities,” Shilpa Medicare said in a BSE filing.
Read also: Shilpa Medicare Hyderabad division gets USFDA clearance
Commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.